由于代谢功能障碍而导致的肝纤维化与与肥胖性肝病和亚临床动脉样硬化之间的关系
Daniele Araujo de Azeredo Coutinho1, Jenaine Rosa Godinho1, Raphael Carreiro Moura1
1Universidade Federal Fluminense, Niterói, RJ - Brasil.
Arquivos brasileiros de cardiologia
|September 24, 2025
概括
患有代谢功能障碍相关的脂肪性肝病 (MASLD) 和肝纤维化的人,血管衰老和心血管风险增加. 这可以通过较高的动脉内心介质厚度 (cIMT) 和血管年龄 (VA) 来证明.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 血管生物学 血管生物学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个全球性的健康问题.
- MASLD进展为纤维化会增加肝脏并发症和心血管疾病 (CVD) 的风险.
- 动脉动脉样硬化标志物预测心血管疾病的结果,强调与肝纤维化的联系.
研究的目的:
- 调查MASLD中的肝纤维化与亚临床动脉样硬化之间的关联.
- 在有纤维化的MASLD患者中评估动脉内膜介质厚度 (cIMT),血管年龄 (VA) 和动脉样斑块.
主要方法:
- 对患MASLD风险的参与者进行前性研究.
- 使用超声波和受控减弱参数 (CAP) 测量评估的肝脏肥胖症和纤维化.
- 动脉动脉样硬化通过动脉超声波,cIMT和VA进行评估.
主要成果:
- 包括114名参与者 (84%是女性,中位数年龄为64岁);86.8%患有肥胖症,27.2%患有纤维化.
- 与非纤维化组相比,纤维化组的cIMT和升高的VA显着更高.
- 在T2DM小组中,纤维化与较高的cIMT和VA相关,其时间表年龄超过9年.
结论:
- 患有肝纤维化的MASLD患者表现出加速的血管衰老.
- 纤维化MASLD患者的升高cIMT和VA表明心血管风险增加.
- 这些发现强调了评估MASLD患者血管健康的重要性.
相关概念视频
Atherosclerosis I: Introduction
923
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
Ultrasound II: Endoscopic Ultrasound and FibroScan
560
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
560
Overview of Lipid Metabolism
4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Inflammation
61.7K
Overview
61.7K


